Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro

• Published in: Saudi pharmaceutical journal Vol. 28; no. 11; pp. 1392 - 1401
• Main Authors: Dadashi Noshahr, Karim, Shamsi, Fahimeh, Valtchev, Peter, Kokhaei, Parviz, Hemati, Maral, Reza Akbari Eidgahi, Mohammad, Khaleghian, Ali
• Format: Journal Article
• Language: English
• Published: Saudi Arabia Elsevier B.V 01.11.2020; Elsevier
• Subjects: CD133–targeted Doxil; Cellular binding; Cellular uptake; Cytotoxicity; Doxil; Optimized post-insertion technique; Original; Routine post-insertion technique; Doxil; Cellular uptake; Optimized post-insertion technique; CD133–targeted Doxil; Cytotoxicity; Routine post-insertion technique; Cellular binding
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2020.09.003

In this paper, Doxil coupled with anti-CD133 monoclonal antibodies made by either routine or optimized post-insertion technique, were compared with respect to their size, drug leakage, release pattern and the number of antibodies conjugated per single liposome. The results demonstrated that the number of antibodies conjugated per liposome in the optimized post-insertion technique was almost two times more than those in the routine post-insertion method. However, the drug release and leakage pattern was almost similar between the two methods. Furthermore, anti-tumor activity and therapeutic efficacy of the preferred CD133–targeted Doxil with Doxil was compared in terms of their in vitro binding, uptake, internalization and cytotoxicity against HT-29 (CD133+) and CHO (CD133-) cells. Flow cytometry analyses and confocal laser scanning microscopy results exhibited a significantly higher cellular uptake, binding and internalization of CD133-targeted Doxil in CD+133 cells relative to Doxil. Cytotoxicity results revealed a lower in vitro inhibitory concentration for CD133–targeted Doxil compared to Doxil. However, CHO (CD133-) cells displayed a similar uptake and in vitro cytotoxicity for both CD133-Doxil and non-targeted Doxil. Therefore, the results of this study can exhibit that specific recognition and binding of antibodies with CD133 receptors on HT-29 cells can result in enhanced cellular uptake, internalization and cytotoxicity. The research suggests further investigation for in vivo studies and may offer proof-of-principle for an active targeting concept.